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Purpose: To determine whether increased growth differentiation factor 15 (GDF15) in
aqueous humor (AH) is associatedwithworse visual field loss in patientswith pseudoex-
foliative glaucoma (PXG).
Methods: We recruited 12 patients (6 males, 6 females) with primary open-angle
glaucoma (POAG) or PXG who were scheduled to undergo glaucoma surgery. AH was
obtained from the initial peripheral paracentesis for the planned glaucoma surgery, and
GDF15 levels were quantified with enzyme-linked immunosorbent assay by an investi-
gator masked to clinical information. Humphrey visual field testing was performed as a
part of routine care; results were obtained by reviewing the medical record.
Results:AHGDF15was detectable in patients with POAG and PXG. Increased AHGDF15
was significantly associated with worse mean deviation in patients with POAG (r =
−0.94; 95% confidence interval [CI], −0.99 to −0.33; P = 0.02) and PXG (r = −0.92; 95%
CI, −0.99 to −0.41; P = 0.01).
Conclusions: AH GDF15 is detectable in patients with PXG and POAG. Elevated AH
GDF15 is strongly associated with worse mean deviation in both subgroups. These
findings suggest that GDF15 may be a molecular marker of glaucoma severity that is
generalizable to multiple types of glaucoma regardless of the underlying etiology.
Translational Relevance: This study provides proof of concept that GDF15, amolecular
marker of retinal ganglion stress that was initially identified in rodent models, may have
clinical utility as a measure of glaucoma severity not only in POAG but also in PXG.
Introduction
Glaucoma is a family of diseases character-
ized by neurodegeneration of retinal ganglion cells
(RGCs). The most common cause of secondary, open-
angle glaucoma is pseudoexfoliative glaucoma (PXG),
caused by deposition of amyloid-like fibrillary material
in the trabecular meshwork and consequent obstruc-
tion of aqueous humor (AH) outflow. Compared to
primary open-angle glaucoma (POAG), PXG exhibits
a more serious clinical course, characterized by higher
intraocular pressure (IOP) at the time of diagno-
sis, faster visual field progression, poorer response to
medical therapy, and increased need for surgical inter-
vention.1–5
Similar to managing POAG, one major challenge
of managing PXG is the inability to monitor RGC
neurodegeneration directly. Instead, clinicians rely
on surrogate measurements of RGC health and
function, such as cup-to-disk ratio, nerve fiber
layer thickness, and visual field testing, and known
risk factors of glaucomatous progression, such as
IOP, to guide clinical decisions.6 Therefore, there
is a clinical need for novel molecular markers that
directly measure RGC stress that could be used to
guide treatment decisions in glaucoma, especially in
PXG.
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We recently discovered that growth differentia-
tion factor 15 (GDF15), a member of the trans-
forming growth factor β superfamily, is a molecular
marker of retinal ganglion stress in rodent models.7
Furthermore, we found that GDF15 was elevated in
the AH of patients with POAG with levels increas-
ing stepwise with worse visual field loss by Hodapp-
Parrish-Anderson staging.7 However, since we tested
only patients with POAG, we were unable to determine
whether these findings are generalizable to other types
of glaucoma.
In this single-center, cross-sectional study, we sought
to determine whether AH GDF15 is also detectable in
PXG and whether it also increases with worse visual
field loss in PXG. Since GDF15 is a molecular marker
of retinal ganglion stress in rodents, we hypothesized
that we would observe similar levels of AH GDF15
in patients with PXG as we have previously reported
for patients with POAG. These findings would support
the possibility of using GDF15 as a molecular marker
of glaucoma severity in multiple forms of glaucoma
beyond POAG.
Methods
To determine the appropriate sample size to identify
a significant association between AH GDF15 and
mean deviation, we performed a power analysis using
G*Power 3.1.9.2.8 Estimating a correlation coefficient
between AH GDF15 and mean deviation of r = 0.75
based on our previous data, we calculated a sample size
of N = 9 to achieve 80% power at a two-tailed alpha
of 0.05. To account for the possible need to exclude
some patients, we recruited 12 participants from
Washington University in St. Louis who were treated
by two glaucoma surgeons. Patients were included if
they had POAG or PXG and were determined to
be candidates for combined cataract extraction with
intraocular lens implantation and glaucoma surgery
of any type as part of their usual care. Glaucoma
subtype was determined by the treating physician
based on physical exam findings, visual field testing,
optic nerve head imaging, and gonioscopy, which were
performed in the clinic as a part of routine care. Eyes
were excluded if there was active inflammatory eye
disease, any retinopathy, optic nerve degeneration from
nonglaucomatous causes, or any condition that would
preclude Humphrey visual field (HVF) testing. In the
final analysis, we excluded one patient since it was
determined during retrospective chart review that the
patient had a history of ocular inflammation with
hand-motion vision in the study eye, giving us a final
study sample of N = 11.
This study was approved by the Institutional Review
Board of the Human Research Protection Office of
Washington University in St. Louis. All procedures
adhered to the tenets of the Declaration of Helsinki.
All patients provided written informed consent after
explanation of the nature and possible consequences
of the study. One AH sample was obtained for
each patient in the operating room during the initial
steps of the planned glaucoma surgery as previ-
ously described.7 Briefly, a blunt cannula on a tuber-
culin syringe was inserted into the initial periph-
eral paracentesis and used to remove 50 to 100 μL
AH. The glaucoma surgery was then performed.
Meanwhile, AHwas immediately placed on dry ice and
stored at −80°C until further analysis. GDF15 levels
were measured using the human GDF15 Quantikine
enzyme-linked immunosorbent assay (ELISA) kit
(R&DSystems) with quantification by comparison to a
standard curve with four-parameter logistic regression.
The investigator (A. Santeford) measuring GDF15
levels was masked to clinical information. All GDF15
levels were measured on the same ELISA plate to
minimize interplate variability.
Demographic and clinical information, includ-
ing presurgical baseline IOP, presurgical number
of medication classes, presurgical cup-to-disc ratio,
presurgical retinal nerve fiber layer (RNFL) thick-
ness, and presurgical mean deviation by HVF, were
obtained by retrospective chart review by an inves-
tigator masked to GDF15 levels (JBL). If a partic-
ipant had multiple HVF results available, the one
that was obtained closest in time to the AH collec-
tion date was used. We performed statistical analy-
sis and data visualization using R version 3.6.2 and
RStudio version 1.2.5003. To compare means, we
used the Mann-Whitney U test for two groups or
Kruskal-Wallis one-way analysis of variance for three
groups. We performed post hoc testing with pairwise
Wilcoxon rank-sum tests, with Bonferroni-adjusted
P values to account for multiple comparisons. To deter-
mine relationships between categorical variables, we
used the Fisher exact test; to determine associations
between continuous variables, we calculated Pearson
correlation coefficients and generated linear regression
models. Due to the small sample, we also calculated
Spearman rank correlation coefficients to confirm the
robustness of our results. We also performed sensitiv-
ity analysis by reanalyzing data without high-leverage
values to confirm the robustness of our results. Where
indicated, we also performed some analysis of the data
in the present article alongside data we have previously
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Table. Demographic and Clinical Characteristics of Study Participants
Characteristic POAG PXG P Value
Sex, No.a (%) 0.57b
Male 4 (66.7) 2 (33.3)
Female 2 (33.3) 4 (66.7)
Age, mean (SD) 67.8 (5.8) 73.8 (6.9) 0.13c
Study eye, No. (%) 1.00b
Oculus dexter 4 (66.7) 3 (50.0)
Oculus sinister 2 (33.3) 3 (50.0)
Planned glaucoma surgery,d No. (%) 0.42b
Ab interno goniotomy 2 (33.3) 1 (16.7)
Gonioscopy-assisted transluminal trabeculotomy 1 (16.7) 2 (33.3)
Kahook Dual Blade goniotomy 0 (0.0) 3 (50.0)
Hydrus microstent 1 (16.7) 0 (0.0)
XEN gel stent 1 (16.7) 0 (0.0)
Ahmed glaucoma valve 1 (16.7) 0 (0.0)
Presurgical baseline IOP, mean (SD) 19.0 (8.0) 20.8 (7.3) 0.58c
Presurgical classes of medications,e mean (SD) 2.8 (1.9) 2.7 (0.8) 0.78c
Presurgical cup-to-disc ratio, mean (SD) 0.74 (0.19) 0.77 (0.23) 0.85c
Presurgical RNFL thickness,f mean (SD) 66.5 (20.6) 62.0 (20.2) 1.00c
Presurgical MD, mean (SD) −8.9 (7.3) −10.5 (13.5) 0.66c
aNumber of participants in each category.
bNot statistically significant by Fisher exact test.
cNot statistically significant by Mann-Whitney U test.
dAll participants also had cataract extraction with intraocular lens placement.
eOral carbonic anhydrase inhibitors were considered a separate class.
fData were not available from one patient with POAG and two patients with PXG.
published.7 We considered P < 0.05 to be statistically
significant.
Results
Demographic and clinical characteristics of
the participants are shown in the Table. There
were six male and six female participants. There
were no differences in the sex, age, study eye
laterality, presurgical baseline IOP, presurgical number
of medication classes, presurgical cup-to-disc ratios,
presurgical RNFL thickness, or presurgical mean
deviation (MD) between patients with POAG or PXG.
After AH was obtained, study participants under-
went a variety of glaucoma surgeries, including ab
interno goniotomy, gonioscopy-assisted transluminal
trabeculotomy, Kahook Dual Blade goniotomy (New
World Medical, Rancho Cucamonga, CA), Hydrus
microstent placement (Ivantis, Irvine, CA), XEN gel
stent placement (AqueSys, Taipei, Taiwan), or Ahmed
glaucoma valve placement (New World Medical).
There was no significant difference in the types of
glaucoma surgeries that patients with POAG or PXG
underwent. None of the patients with POAG had a
prior glaucoma surgery; two of the patients with PXG
had previous selective laser trabeculoplasty (SLT), and
one patient with PXG had previous SLT and Ahmed
glaucoma valve placement.
AH GDF15 was detectable in patients with POAG
and PXG (Fig. 1). Although we did not recruit healthy
patients without glaucoma in this study, these AH
GDF15 levels were significantly elevated compared to a
historical control group of patients without glaucoma,
which we published previously (P < 0.001; Fig. 2).
In fact, in this past study, ∼88% of patients without
glaucoma had AH GDF15 levels that were below the
limit of detection of commercially available ELISA.
To determine whether AH GDF15 levels increase
stepwise with worse visual field loss, we also compared
the relationship between AH GDF15 and severity
of visual field loss between patients with POAG
and PXG. For all patients, HVF results obtained
through routine clinical care were available within a
median of 0.19 years from the day of AH collection
(range, 0.033 to 2.41 years). In all patients, there was
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Figure 1. AH GDF15 was detectable in patients with POAG and
those with PXG. Height of bars represents mean; filled circles repre-
sent individual patients.
Figure 2. There was a significant difference in AH GDF15 levels
when comparing the patients with POAG and PXG in this study
(“POAG/PXG”; right column in red) to historical patients with POAG
(“POAG”; middle column in green) and historical healthy patients
without glaucoma (“Control”; left column in blue), which are both
from Ban et al.7 (Kruskal-Wallis one-way analysis of variance; P <
0.001). Post hoc testing by pairwise Wilcoxon rank-sum tests with
Bonferroni-adjusted P values to account for multiple comparisons
showed that there was a significant difference between POAG/PXG
and control (P < 0.001) and between POAG and control (P < 0.001).
There was no significant difference between POAG/PXG and POAG
(P = 0.084). Filled circles represent individual patients.
a strong association between AH GDF15 and MD
on HVF testing (r = −0.80, 95% confidence inter-
val [CI], −0.95 to −0.39; P = 0.003) (Fig. 3A). This
association was similar when examining patients with
POAG and PXG separately (POAG: r = −0.94; 95%
CI, −0.99 to −0.33; P = 0.02; PXG: r = −0.92; 95%
CI, −0.99 to −0.41; P = 0.01) (Fig. 3B). We found
similar associations with nonparametric Spearman
rank correlation coefficients (POAG: ρ = −0.80; PXG:
ρ = −0.94), demonstrating the robustness of our
results despite the small sample size. Although there
were two patients with PXG whose AH GDF15 levels
appeared to be distinctly different from the other
four patients, Grubbs’ test revealed that they were not
outliers at the two-tailed α = 0.05 level. Moreover, the
significant association remained even when omitting
these two high-leverage data values (r = −0.95;
ρ = −1.00; Fig. 3C), strengthening the robustness of
our findings.
To determine the magnitude of the effect size,
we also generated a linear regression model with the
independent variable of AH GDF15 and the depen-
dent variable of MD. IncreasedAHGDF15was signif-
icantly associated with worse MD (β = −0.042; 95%
CI, −0.065 to −0.018; P = 0.003). When examining
patients with POAG and PXG separately, we found
similar effect sizes (POAG: β = −0.12; 95% CI, −0.21
to−0.040;P= 0.02; PXG:β = −0.050; 95%CI,−0.081
to −0.020; P = 0.01). Cumulatively, our findings
suggest that AH GDF15 is detectable in PXG and
POAG and similarly increases with worse visual field
loss in both disease subtypes.
Discussion
In this study, we found that AH GDF15 is
detectable in patients with PXG, similar to our
previous observations in patients with POAG. Of
interest, we found similar associations between
elevations in AH GDF15 and visual field loss in
patients with POAG and PXG. These findings suggest
that elevations in AH GDF15 are likely associated
with worse glaucoma severity and not dependent
on the underlying pathophysiology, supporting the
idea that GDF15 as a molecular marker could be
generalizable to PXG and perhaps other forms of
glaucoma.
These findings are significant since they may lead
to improved treatment algorithms for PXG, which
are needed given its challenging clinical trajectory.
One strength of this study was deliberate masking to
mitigate the risk of bias. The investigator reviewing
the medical record to obtain demographic and clini-
cal information was masked to GDF15 levels, while the
investigator measuring AH GDF15 levels was masked
to clinical information. Furthermore, our consistent
findings in patients with POAG compared to our prior
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Figure 3. (A) There was a strong negative association between AH GDF15 and mean deviation on Humphrey visual field testing when
patients with POAG and PXG were analyzed together. (B) There was a similar negative association when analyzing patients with POAG and
PXG separately. (C) The negative association remained significant when reanalyzing the data without the two high-leverage patients with
PXG, strengthening the robustness of our findings. Dashed lines indicate lines of best fit; shaded regions indicate 95% confidence interval
bands; filled circles represent individual patients.
work7 attest to the rigor of our study design and
analytic approach.
Although we exceeded the sample size necessary
by power analysis and found significant associations,
our small sample size did not permit us to perform
multivariable analysis to control for possible confound-
ing variables, including prior glaucoma surgery. The
fact that some patients with PXG had prior glaucoma
surgery may have influenced the results of this study.
Moreover, in this study, no patients with POAG or
PXG had AH GDF15 levels below the limit of detec-
tion of commercially available ELISA, while some
patients from our previous study did.We speculate that
this difference may have arisen due to the worse visual
field loss of the patients recruited for this study. Further
studies examining the analytical and biological variabil-
ity of AH GDF15 not only at single time points but
also in a longitudinal fashion are essential to further
characterize the temporal dynamics of AH GDF15
elevation in relation toRGC stress and ultimate demise.
Finally, as is the case for all molecular markers, it will
be essential to rigorously examine the sensitivity and
specificity of AHGDF15 given that serumGDF15 has
been reported as a molecular marker for other systemic
diseases, including cardiovascular diseases, obesity,
kidney diseases, and diabetes. These future studies are
essential before we can fully understand the transla-
tional possibilities of GDF15 as amolecularmarker for
glaucoma.
Acknowledgments
The authors thank Mae Gordon (Washington
University in St. Louis) for assistance with statistical
analysis.
Supported by the Glaucoma Foundation (RSA),
the Jeffrey Fort Innovation Fund (RSA), the Bill
and Emily Kuzma Family Gift for Retinal Research
(RSA), National Institutes of Health (NIH) grant P30
EY02687 (Vision Core Grant), and an unrestricted
grant from Research to Prevent Blindness to the
Department of Ophthalmology and Visual Sciences
at Washington University in St. Louis. JBL was
supported by NIH grants T32 GM07200, UL1
TR002345, and TL1 TR002344. The funders had no
role in the design or conduct of this research.
Disclosure: J.B. Lin, None; A. Sheybani, None;
A. Santeford, None; A. De Maria, None; R.S. Apte,
consultant for QBio and listed on patient application
for intellectual property related to GDF15 (C, P)
References
1. Konstas AG, Mantziris DA, Stewart WC. Diurnal
intraocular pressure in untreated exfoliation and
Downloaded from tvst.arvojournals.org on 10/22/2020
GDF15 in Pseudoexfoliative Glaucoma TVST | September 2020 | Vol. 9 | No. 10 | Article 16 | 6
primary open-angle glaucoma. Arch Ophthalmol.
1997;115:182–185.
2. Vesti E, Kivelä T. Exfoliation syndrome and exfoli-
ation glaucoma. Prog Retin Eye Res. 2000;19:345–
368.
3. Kim JH, Rabiolo A, Morales E, et al. Risk factors
for fast visual field progression in glaucoma. Am J
Ophthalmol. 2019;207:268–278.
4. Chan TCW, Bala C, Siu A, Wan F, White A. Risk
factors for rapid glaucoma disease progression. Am
J Ophthalmol. 2017;180:151–157.
5. Tarkkanen AHA, Kivelä TT. Comparison of
primary open-angle glaucoma and exfoliation
glaucoma at diagnosis. Eur J Ophthalmol.
2015;25:137–139.
6. BanN, Siegfried CJ, Apte RS.Monitoring neurode-
generation in glaucoma: therapeutic implications.
Trends Mol Med. 2018;24:7–17.
7. BanN, SiegfriedCJ, Lin JB, et al.GDF15 is elevated
in mice following retinal ganglion cell death and in
glaucoma patients. JCI Insight. 2017;2:91455.
8. Faul F, Erdfelder E, Buchner A, Lang A-G. Statisti-
cal power analyses using G*Power 3.1: tests for cor-
relation and regression analyses. Behav Res Meth-
ods. 2009;41:1149–1160.
Downloaded from tvst.arvojournals.org on 10/22/2020
